Exelixis' Cabometyx misses survival target in liver cancer t...

Exelixis has suffered a blow to its efforts to expand the use of Cabometyx into additional indications after reporting mixed results in a phase 3 trial in liver cancer.

Merck gets a leg-up for Keytruda in first-line kidney cancer

New phase 3 data have shored up the position of Merck & Co’s cancer immunotherapy Keytruda in the increasingly competitive first-line kidney cancer market. 

Exelixis takes $20m option Iconic/Zymeworks' cancer ADC

Exelixis has taken a $20 million option to license in an antibody-drug conjugate cancer (ADC) drug from Iconic, with clinical trials expected to start next year.

FDA kicks off review of second kidney cancer combo based on ...

Bristol-Myers Squibb could be mere months away from claiming a second US approval for an Opdivo-based combination immunotherapy that will help defend its first-line kidney cancer franchise.

Exelixis doubles down on ADCs for cancer with NBE, Catalent ...

Exelixis made its name developing small-molecule drugs for cancer, so a new pair of deals focused on antibody-drug conjugates reinforces a recent change of direction for the biotech.

BMS gets an important win for Opdivo combination in kidney c...